JP2023500020A5 - - Google Patents
Info
- Publication number
- JP2023500020A5 JP2023500020A5 JP2022516283A JP2022516283A JP2023500020A5 JP 2023500020 A5 JP2023500020 A5 JP 2023500020A5 JP 2022516283 A JP2022516283 A JP 2022516283A JP 2022516283 A JP2022516283 A JP 2022516283A JP 2023500020 A5 JP2023500020 A5 JP 2023500020A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- composition according
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382990.0 | 2019-11-11 | ||
| EP19382990.0A EP3818983A1 (en) | 2019-11-11 | 2019-11-11 | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
| PCT/EP2020/081674 WO2021094331A1 (en) | 2019-11-11 | 2020-11-10 | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500020A JP2023500020A (ja) | 2023-01-04 |
| JP2023500020A5 true JP2023500020A5 (cg-RX-API-DMAC10.html) | 2023-10-26 |
| JP7808029B2 JP7808029B2 (ja) | 2026-01-28 |
Family
ID=68610132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516283A Active JP7808029B2 (ja) | 2019-11-11 | 2020-11-10 | 心血管石灰化の治療、進行の抑制、または予防における使用のためのイノシトールリン酸化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220339171A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3818983A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7808029B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20220099957A (cg-RX-API-DMAC10.html) |
| CN (2) | CN114585367A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020381775B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3156023A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL292118B2 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2022004971A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021094331A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021003653A (es) | 2018-10-11 | 2021-06-23 | Sanifit Therapeutics S A | Inositol fosfatos para el tratamiento de calcificacion ectopica. |
| CN113712976B (zh) * | 2021-10-21 | 2023-02-24 | 中国人民解放军海军军医大学 | 小分子化合物肌醇六磷酸酯钠水合物在制备抗SARS-CoV-2药物中的应用 |
| WO2024047037A1 (en) | 2022-08-30 | 2024-03-07 | ETH Zürich | Compositions for parenteral sustained release delivery of hydrophilic drugs |
| US20250217970A1 (en) * | 2023-12-28 | 2025-07-03 | Case Western Reserve University | Risk prediction of heart failure |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| CA2132012C (en) | 1992-03-25 | 2003-04-22 | John W. Shell | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ATE302597T1 (de) | 1997-06-06 | 2005-09-15 | Depomed Inc | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
| NZ518739A (en) | 1999-11-02 | 2004-12-24 | Depomed Inc | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| MXPA02007254A (es) | 2000-02-04 | 2002-12-09 | Depomed Inc | Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero. |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| WO2002096404A1 (en) | 2001-05-29 | 2002-12-05 | Depomed Development Ltd | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| ES2232302B1 (es) | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | Myo-inositol hexafosfato para uso topico. |
| ES2288126B2 (es) | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
| ES2332636B1 (es) | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
| MX347723B (es) | 2011-09-29 | 2017-05-10 | Eth Zuerich | Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile. |
| EP2579036A1 (en) | 2011-10-06 | 2013-04-10 | Laboratorios Sanifit, S.L. | Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200 |
| ES2495666B1 (es) * | 2013-03-15 | 2015-08-10 | Laboratoris Sanifit, S.L. | Uso de derivados con enlaces c-o-p en pacientes con fallo renal |
| US9364490B2 (en) * | 2013-03-15 | 2016-06-14 | Laboratoris Sanifit, S.L. | Use of derivatives containing C—O—P bonds in patients with kidney failure |
| SMT202100406T1 (it) | 2015-12-11 | 2021-09-14 | Eth Zuerich | Derivati di inositolo per l'uso nella cristallizzazione patologica |
| ES2762984T3 (es) | 2015-12-11 | 2020-05-26 | Eth Zuerich | 4,6-di-(O-tiofosfato)-inositol-1,2,3,5-tetra-O-sulfato para la infección por C. difficile |
-
2019
- 2019-11-11 EP EP19382990.0A patent/EP3818983A1/en not_active Withdrawn
-
2020
- 2020-11-10 CN CN202080071356.8A patent/CN114585367A/zh active Pending
- 2020-11-10 EP EP20808309.7A patent/EP4058030A1/en active Pending
- 2020-11-10 AU AU2020381775A patent/AU2020381775B2/en active Active
- 2020-11-10 MX MX2022004971A patent/MX2022004971A/es unknown
- 2020-11-10 CN CN202610080635.XA patent/CN122080055A/zh active Pending
- 2020-11-10 CA CA3156023A patent/CA3156023A1/en active Pending
- 2020-11-10 KR KR1020227014412A patent/KR20220099957A/ko active Pending
- 2020-11-10 JP JP2022516283A patent/JP7808029B2/ja active Active
- 2020-11-10 WO PCT/EP2020/081674 patent/WO2021094331A1/en not_active Ceased
-
2022
- 2022-03-17 US US17/697,729 patent/US20220339171A1/en not_active Abandoned
- 2022-04-10 IL IL292118A patent/IL292118B2/en unknown
-
2025
- 2025-01-17 US US19/030,283 patent/US20250295676A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE60245B1 (en) | A synergistic combination of amantadine and selegiline | |
| JP2011173928A5 (cg-RX-API-DMAC10.html) | ||
| JP2018531605A5 (cg-RX-API-DMAC10.html) | ||
| JP2025148449A5 (cg-RX-API-DMAC10.html) | ||
| JP2001520656A (ja) | 抗腫瘍剤としてのホルボールエステル類 | |
| JP2018532797A5 (cg-RX-API-DMAC10.html) | ||
| JP6359583B2 (ja) | 肝細胞がんの予防及び／又は治療のための医薬 | |
| JP2022521119A5 (cg-RX-API-DMAC10.html) | ||
| KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
| KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
| CN117243956A (zh) | 一种用于治疗结核分枝杆菌感染的药物组合物及其应用 | |
| WO2021037933A1 (en) | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer | |
| JPH0121132B2 (cg-RX-API-DMAC10.html) | ||
| TW200808327A (en) | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma | |
| JP2024531799A5 (cg-RX-API-DMAC10.html) | ||
| JP5792322B2 (ja) | ビタミンｄおよびメトホルミン含有医薬組成物 | |
| JP2016503035A (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
| TW202038931A (zh) | 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物 | |
| CN102309491B (zh) | 一种替加氟、吉美斯特复方注射液 | |
| CN110891574B (zh) | 用于预防和/或治疗肝细胞癌的美格列明 | |
| WO2021223664A1 (en) | Methods for treating coronavirus infections | |
| US20210315898A1 (en) | Combination therapy for treating cancer | |
| TW536400B (en) | Pharmaceutical composition for the treatment of immunodeficiency disease which cause by HIV infection | |
| JP4253371B2 (ja) | 筋クランプ治療剤 | |
| CN112451678B (zh) | HMG-CoA还原酶抑制剂-维D的药物组合物及用途 |